Abstract
Novel therapies that target vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways have transformed that manner in which patients with advanced renal cancer are managed; but because these agents are not curative, disease progression eventually ensues. Data on optimal sequential use of these therapies are lacking, and efforts to explore combined use of targeted agents have been hampered by intolerable toxicities. Evidence …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
